Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.53 USD
-0.14 (-8.38%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $1.54 +0.01 (0.65%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLSD 1.53 -0.14(-8.38%)
Will CLSD be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CLSD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLSD
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
CLSD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Other News for CLSD
12 Health Care Stocks Moving In Wednesday's After-Market Session
Clearside Biomedical appoints Chong as CMO
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Clearside Biomedical appoints Chong as Chief Medical Officer
12 Health Care Stocks Moving In Thursday's Intraday Session